Eleven Therapeutics vs Immunai

Eleven Therapeutics vs Immunai, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Eleven Therapeutics is on 56/100 and Immunai on 69/100.

Eleven Therapeutics logo
Eleven TherapeuticsIsraeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.
Try Eleven Therapeutics
Immunai logo
ImmunaiMapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Try Immunai

Where each one leads

Eleven Therapeutics

  • agent readiness: 40/100 against 32/100
  • headcount growth: +17.6% against +13.0%

Immunai

  • our overall score: 69/100 against 56/100
  • domain rating: 46/100 against 13/100
  • headcount: 179 against 28
  • funding raised: $295M against $22.0M
  • LinkedIn following: 26,832 against 5,528

At a glance

MeasureEleven TherapeuticsImmunai
What it isIsraeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
CategoryHealthcare, Life Sciences, Therapeutics, BiotechHealthcare, Immunology, Data, Analytics
Sells toBusiness modelB2BB2B
OfferingPlatformSoftware
Founded20172019
HeadquartersLondon, United KingdomNew York, United States
StatusActiveActive

Size, funding and growth

MeasureEleven TherapeuticsImmunai
Employees28179
Headcount growthLast 12 months+17.6%+13.0%
Open roles4Not published
Total funding$22.0M$295M
Latest roundSeedSeries B
ValuationNot published$1.0B
LinkedIn followers5,52826,832

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureEleven TherapeuticsImmunai
StartupHub scoreOur 0-100 rating56/10069/100
Traction51/10060/100
Team70/10070/100
Search visibility30/10039/100
Quality58/10078/100
Agent readinessHow well an AI agent can read and act on the siteD (40/100)F (32/100)
Domain ratingLink authority, 0-10013/10046/100

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureEleven TherapeuticsImmunai
CDNCloudflareNot detected
CMSWebflowWordPress
FrameworksNot detectedJquery, Bootstrap
AnalyticsNot detectedGoogle Tag Manager

Eleven Therapeutics vs Immunai: common questions

Which is better, Eleven Therapeutics or Immunai?

On our 0-100 score Immunai rates higher (69/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.

How do Eleven Therapeutics and Immunai compare on the numbers?

Eleven Therapeutics leads on agent readiness (40/100 against 32/100), headcount growth (+17.6% against +13.0%). Immunai leads on our overall score (69/100 against 56/100), domain rating (46/100 against 13/100), headcount (179 against 28), funding raised ($295M against $22.0M), LinkedIn following (26,832 against 5,528).

Read the full Eleven Therapeutics review and pricing or the Immunai review and pricing. You can also browse other Eleven Therapeutics alternatives we track.